U S Stem Cell Inc Revenue Growth Rates (USRM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
U s Stem Cell Inc   (NONE: USRM)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

USRM's Revenue Growth by Quarter and Year

U S Stem Cell Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

USRM Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December 0.02
3rd Quarter September 0.01
2nd Quarter June 0.02
1st Quarter March 0.02
FY 0.07

USRMs Annual Revenue
U S Stem Cell Inc 's Revenue in the fiscal year 2022 $ 0.08 millions
U S Stem Cell Inc 's Revenue in the fiscal year 2021 $ 0.20 millions
U S Stem Cell Inc 's Revenue in the fiscal year 2020 $ 0.28 millions
U S Stem Cell Inc 's Revenue in the fiscal year 2019 $ 3.07 millions
U S Stem Cell Inc 's Revenue in the fiscal year 2018 $ 6.70 millions




USRM Revenue fourth quarter 2022 Y/Y Growth Comment
U S Stem Cell Inc reported decrease in Revenue in the fourth quarter 2022 by -0.13% to $ 0.02 millions, from the same quarter in 2021.
The decrease in the fourth quarter 2022 U S Stem Cell Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 305.87%.

Looking into fourth quarter 2022 results within Medical Laboratories industry 29 other companies have achieved higher Revenue growth. While U S Stem Cell Inc ' s Revenue decline of -0.13% ranks overall at the positon no. 3351 in the fourth quarter 2022.


USRM Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December -0.13 % -83.33 % -61.29 % -81.33 %
3rd Quarter September -83.33 % 0 % -62.5 % -89.33 %
2nd Quarter June -50 % 0 % -96.92 % -28.57 %
1st Quarter March -75 % 33.33 % -95.42 % -23.39 %
FY   -65.01 % -28.57 % -90.91 % -

Financial Statements
U S Stem Cell Inc 's fourth quarter 2022 Revenue $ 0.02 millions USRM's Income Statement
U S Stem Cell Inc 's fourth quarter 2021 Revenue $ 0.02 millions Quarterly USRM's Income Statement


USRM Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December 99.74 % -66.67 % 100 % 93.75 %
3rd Quarter September -50 % 50 % 50 % -87.69 %
2nd Quarter June 0 % -50 % -33.33 % -0.76 %
1st Quarter March 0 % -33.33 % -80.65 % -21.08 %
FY (Year on Year)   -65.01 % -28.57 % -90.91 % -


Back to USRM Growth rate Comparisons >> Back to USRM Growth rate Comparisons >>


Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #30
Healthcare Sector #492
Overall #3351

Revenue Y/Y Growth Statistics
High Average Low
7594.94 % 305.87 % -100 %
(Sep 30 2017)   (Sep 30 2021)
Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #30
Healthcare Sector #492
Overall #3351
Revenue Y/Y Growth Statistics
High Average Low
7594.94 % 305.87 % -100 %
(Sep 30 2017)   (Sep 30 2021)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

U S Stem Cell Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
380.18 % 23.7 % -100 %
(Jun 30 2013)  


USRM's IV. Quarter Q/Q Revenue Comment
U s Stem Cell Inc achieved in the IV. Quarter 2022 above company average sequential Revenue jump of 99.74%, to $ 0.02 millions, from $0.01 millions in the third quarter.
USRM is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry only one company achieved higher sequential Revenue growth. While U S Stem Cell Inc 's Revenue growth quarter on quarter, overall rank is 220.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #70
Overall #220
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #70
Overall #220
Revenue Q/Q Growth Statistics
High Average Low
380.18 % 23.7 % -100 %
(Jun 30 2013)  


USRM's IV. Quarter Q/Q Revenue Comment
U s Stem Cell Inc achieved in the IV. Quarter 2022 above company average sequential Revenue jump of 99.74%, to $ 0.02 millions, from $0.01 millions in the third quarter.
USRM is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry only one company achieved higher sequential Revenue growth. While U S Stem Cell Inc 's Revenue growth quarter on quarter, overall rank is 220.


U S Stem Cell Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 0.08 $ 0.09 $ 0.13 $ 0.14 $ 0.20
Y / Y Revenue Growth (TTM) -59.13 % -70.71 % -57.05 % -54.05 % -27.55 %
Year on Year Revenue Growth Overall Ranking # 4017 # 0 # 0 # 0 # 3897
Seqeuential Revenue Change (TTM) -4.22 % -33.46 % -7.82 % -30.42 % -31.36 %
Seq. Revenue Growth (TTM) Overall Ranking # 3848 # 3676 # 3440 # 3486 # 3785


Cumulative Revenue growth Comment
U S Stem Cell Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2022. If the fiscal year would end in Dec 31 2022, U S Stem Cell Inc 's annual Revenue drop would be -59.13% year on year to $0 millions.

In the Healthcare sector 574 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 4017.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 32
Healthcare Sector # 575
Overall # 4017

Revenue TTM Y/Y Growth Statistics
High Average Low
85.78 %
 -49.64 %
-590.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 32
Sector # 538
S&P 500 # 3848
Cumulative Revenue growth Comment
U S Stem Cell Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2022. If the fiscal year would end in Dec 31 2022, U S Stem Cell Inc 's annual Revenue drop would be -59.13% year on year to $0 millions.

In the Healthcare sector 574 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 4017.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 32
Healthcare Sector # 575
Overall # 4017

Revenue TTM Y/Y Growth Statistics
High Average Low
85.78 %
-49.64 %
-590.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 32
Sector # 538
S&P 500 # 3848




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
USRM's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Amgen Inc -0.10%$ -0.102 millions
Bausch Health Companies Inc -0.14%$ -0.137 millions
Bio rad Laboratories Inc -0.34%$ -0.339 millions
Nrc Health-0.40%$ -0.402 millions
Asensus Surgical Inc -0.48%$ -0.485 millions
Bausch and Lomb Corp-0.50%$ -0.500 millions
Teleflex Incorporated-0.51%$ -0.514 millions
Elite Pharmaceuticals Inc -0.62%$ -0.619 millions
Meihua International Medical Technologies Co Ltd-0.66%$ -0.665 millions
Ambrx Biopharma Inc -0.71%$ -0.711 millions
Chemed Corporation-0.85%$ -0.851 millions
Vycor Medical Inc -0.90%$ -0.899 millions
Fonar Corporation-0.91%$ -0.911 millions
Davita Inc -0.92%$ -0.920 millions
Syneos Health Inc -0.98%$ -0.984 millions
Reshape Lifesciences Inc-1.02%$ -1.018 millions
Accuray Incorporated-1.30%$ -1.303 millions
Bellicum Pharmaceuticals Inc -1.57%$ -1.575 millions
Pliant Therapeutics Inc -1.70%$ -1.701 millions
Royalty Pharma Plc-1.73%$ -1.729 millions
Precipio inc -1.81%$ -1.807 millions
Integra Lifesciences Holdings Corp-1.85%$ -1.850 millions
Nexgel Inc -1.88%$ -1.876 millions
Novartis Ag-1.98%$ -1.984 millions
Theravance Biopharma inc -1.99%$ -1.987 millions
Orthofix Medical Inc -2.27%$ -2.267 millions
Travere Therapeutics Inc -2.41%$ -2.412 millions
Heska Corporation-2.54%$ -2.542 millions
Sangamo Therapeutics Inc -2.70%$ -2.701 millions
Glaukos Corp-2.75%$ -2.748 millions


About U S Stem Cell Inc Revenue Growth Rates (USRM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: U s Stem Cell Inc (CIK 1388319).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001185185-23-000339
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: U s Stem Cell Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.